A new science is being born.
In under a decade, partial reprogramming has moved from a radical hypothesis to a field attracting billions in capital, Nobel laureates, and the first FDA-cleared human trial. Here is the full landscape.
Across 331 deals in 2024 alone — a 220% increase from 2023. Cellular reprogramming is the most capital-intensive longevity domain.
Largest Single Company Raise
$5.56B (Altos Labs cumulative)
Tracxn (2022-2025)
Cellular Reprogramming Subsector
Most capital-intensive longevity domain
New Market Pitch Longevity Report (2024)
First Partial Reprogramming Human Trial
NCT07290244 (Life Biosciences ER-100)
ClinicalTrials.gov / FDA IND clearance (2026)
Companies in Partial Reprogramming
18+ active companies globally
Compiled from multiple sources (2026)
Companies
18 companies driving partial reprogramming and cellular rejuvenation, sorted by total funding.
Altos Labs
$5.56BTransform medicine through cellular rejuvenation programming to restore cell health and resilience.
In vivo partial epigenetic reprogramming using Yamanaka factors to reverse cellular aging without inducing pluripotency. Acquired Dorian Therapeutics (senotherapeutics) in May 2025.
Preclinical/Early clinical. Extended mouse lifespan via targeted partial reprogramming (2024). Early human safety testing reportedly began August 2025.
altoslabs.comCalico (California Life Company)
$3.5B+ (Alphabet subsidiary + AbbVie partnership)Tackle the challenge of aging and age-related diseases to enable people to lead longer and healthier lives.
Biology of aging research across multiple modalities: small molecules, genetics, and computational biology. Focused on understanding fundamental aging biology and developing interventions for age-related diseases.
Clinical-stage (though pivoting). Lead drug fosigotifator failed Phase II/III for ALS (Jan 2025). AbbVie partnership terminated Nov 2025 after $1B+ invested. Continuing immuno-oncology and neurodegeneration programs.
calicolabs.comRetro Biosciences
$1.18BAdd 10 years to healthy human lifespan by targeting the cellular hallmarks of aging.
Multi-modal longevity platform: partial reprogramming, autophagy modulation, and plasma-inspired therapies. AI-driven drug discovery for cellular rejuvenation of blood and brain cells.
Clinical trials initiated for three drugs in 2025, including RTR242, a small-molecule autophagy activator, entering early-stage trial in Australia. Separate partial reprogramming program remains preclinical. Blood stem cell therapy and metabolic caloric-restriction mimetics in development.
retro.bioNewLimit
$325M+Extend human healthspan by reversing age-related epigenetic changes in targeted tissues.
Epigenetic reprogramming via mRNA delivered in lipid nanoparticles to specific tissues. Uses machine learning to identify transcription factor payloads that restore youthful gene expression.
Preclinical, approaching IND. Lead program: mRNA-based liver rejuvenation for alcohol-related liver disease. Selected lead reprogramming payload in Sept 2025. Expanding into immune cell rejuvenation and vascular endothelial cell programs. Valuation: $1.62B.
newlimit.comLife Biosciences
$158M+Redefine aging by developing cellular rejuvenation therapies that reverse and prevent age-related diseases.
Partial Epigenetic Reprogramming (PER) platform using three Yamanaka factors (OCT4, SOX2, KLF4) delivered via AAV gene therapy to restore aged/damaged cells. Acquired Iduna Therapeutics (2021).
CLINICAL STAGE. FDA cleared IND for ER-100 in Jan 2026 -- the FIRST-EVER partial reprogramming therapy in human clinical trials. Phase 1 (NCT07290244) enrolling patients with open-angle glaucoma and NAION. MASH program in preclinical.
lifebiosciences.comLoyal
$150M+Develop the first FDA-approved drugs to extend healthy lifespan in dogs.
Developing FDA-regulated drugs to extend healthy canine lifespan by targeting metabolic dysfunction associated with aging. Uses geroscience approach (GLP-1/IGF-1 pathways).
MOST ADVANCED in animal longevity. LOY-002 (daily oral tablet for senior dogs 10+): FDA accepted both RXE (efficacy) and TAS (safety) packages for conditional approval. STAY study: largest veterinary trial in history (1,000+ dogs, 70 clinics). On track for first FDA-approved lifespan extension drug.
loyal.comGordian Biotechnology
$60MDiscover therapies that cure age-related diseases through patient-predictive in vivo screening of gene targets.
High-throughput in vivo screening platform (Mosaic Screening + Pythia AI) that tests thousands of gene therapies simultaneously in single animals to predict clinical outcomes for age-related diseases.
Platform validated. Proof-of-concept predicts MASH clinical outcomes with >80% accuracy. Lead programs in osteoarthritis and obesity. Pharma partnerships in development.
gordian.bioRubedo Life Sciences
$52MEngineer therapies that eliminate the senescent cells driving chronic age-related diseases.
Small-molecule senolytics engineered to selectively target and clear senescent cells responsible for chronic age-related inflammation and disease. Precision senolytic approach.
Preclinical. $40M Series A closed April 2024. Lead candidate RLS-1496 is a topical senolytic for chronic atopic dermatitis and psoriasis. Additional lung programs in development.
rubedolife.comConception Biosciences
$38MAdvance the future of fertility by making human eggs from stem cells.
In vitro gametogenesis (IVG): converting blood-derived iPSCs into functional human egg cells using developmental biology and computational approaches. Intersects with reprogramming through iPSC generation.
Research stage. Working on converting induced pluripotent stem cells into oocytes. Advancing through developmental biology milestones toward functional gametes.
conception.bioTurn Biotechnologies
$30.1MDevelop mRNA medicines that restore youthful cell function to combat age-related diseases.
Proprietary Epigenetic Reprogramming of Age (ERA) platform using mRNA to transiently express reprogramming factors, restoring youthful cellular function without full dedifferentiation. Acquired ARMMs vesicular delivery tech in March 2025.
Preclinical, approaching clinical. $300M licensing deal with HanAll Biopharma for ophthalmology/otology. Plans to initiate clinical trials for skin rejuvenation in 2026. Klotho Neuro acquisition LOI expired Oct 2025 (assets remain with Turn).
turn.bioOisin Biotechnologies
$27.5MDevelop genetic medicines that target and eliminate senescent cells to combat age-related frailty and disease.
Lipid nanoparticle-delivered 'suicide gene' therapy that selectively eliminates senescent cells (SENSOlytic) and unwanted fat cells (SENSOlipidic). Targets p16-positive senescent cells.
Late preclinical. $15M Series A (July 2024) led by AbbVie Ventures. GLP tox studies initiated late 2024, IND filing planned 2025, Phase 1 target 2026. Lead programs in sarcopenia and fat reduction.
oisinbio.comShift Bioscience
$16MUse AI and cell simulation to discover safe gene-based rejuvenation therapies that go beyond Yamanaka factors.
AI-powered 'virtual cell' platform that models epigenetic states to identify safe, non-Yamanaka rejuvenation gene targets. Lead candidate SB000 rejuvenates epigenetic clocks by 3-10 years per month of overexpression.
Preclinical discovery. Identified novel rejuvenation gene SB000 selectively expressed in early development. Building IP portfolio around novel gene targets. Funded through 2026.
shiftbioscience.comMarble Therapeutics
$15M (Seed)Develop gene therapies for tissue rejuvenation using insights from George Church's aging research.
Skin-targeted AAV gene delivery for rejuvenation. Spun out from George Church's lab at Harvard. Part of the broader Church lab ecosystem of longevity-focused startups.
Early preclinical. Developing AAV-based gene therapies for skin indications. Connected to Cambrian Bio portfolio.
Rejuvenate Bio
$14.6MUse gene therapy to treat age-related diseases, starting with man's best friend and translating to humans.
AAV gene therapy overexpressing longevity genes sTGFbetaR2 and FGF21 to reduce TGF-beta1 and boost FGF21 levels. Dogs-first strategy before human translation.
Preclinical. Lead program for canine mitral valve disease (MVD) in partnership with ACKCS Club. Pipeline includes RJB-0402 (liver-directed FGF21 for metabolic diseases). Multiple canine programs before human IND.
rejuvenatebio.comAgeX Therapeutics (merged into Serina Therapeutics)
$13.16M+ (pre-merger)Merged
Develop regenerative therapeutics and an iTR platform to restore youthful tissue repair capacity.
Pluripotent stem cell-derived therapies for age-related diseases: brown adipose tissue (AGEX-BAT1), vascular progenitor cells (AGEX-VASC1), and iTR drug platform to restore regenerative potential.
MERGED. Completed all-stock merger with Serina Therapeutics in March 2024. Combined entity operates as Serina Therapeutics focusing on neurological diseases. Original aging pipeline may be deprioritized.
agexinc.comYouthBio Therapeutics
Undisclosed (early-stage)Develop tissue-specific gene therapies that partially reprogram cells to treat neurodegenerative and age-related diseases.
Tissue-specific AAV gene therapy delivering partial reprogramming factors (OSKM) to targeted tissues. Lead program YB002 targets dentate gyrus neurons in hippocampus for Alzheimer's disease.
Pre-IND. Positive FDA INTERACT meeting Sept 2025: agency confirmed bioactivity and supports path to first-in-human trial. Preclinical data shows cognitive improvement in aged mice. Aiming for clinical trials in ~3 years.
youthbiotx.comIduna Therapeutics (Life Biosciences subsidiary)
Acquired by Life Biosciences (Sept 2021)Acquired
Enable tissue regeneration through partial epigenetic reprogramming in non-regenerative organs.
Epigenetic reprogramming for tissue regeneration in organs that cannot self-repair. Technology forms the core of Life Biosciences' PER platform for optic nerve and liver rejuvenation.
Integrated into Life Biosciences pipeline. Technology underpins ER-100 program now in Phase 1 clinical trials (NCT07290244). NOT acquired by AstraZeneca -- acquired by Life Biosciences in 2021.
lifebiosciences.comDorian Therapeutics (acquired by Altos Labs)
Acquired by Altos Labs (May 2025)Acquired
Develop senoblocker drugs that neutralize cellular senescence to restore tissue regeneration.
Small-molecule 'senoblockers' that neutralize harmful effects of senescent cells while reactivating natural repair mechanisms. Distinct from senolytics -- blocks senescence signals rather than killing cells.
Integrated into Altos Labs. Preclinical efficacy demonstrated in models of lung fibrosis and osteoarthritis prior to acquisition.
altoslabs.comClinical Trials
Where the science meets regulation. Active and upcoming reprogramming-adjacent programs.
| Trial | Sponsor | Indication | Phase | CT.gov ID | Status |
|---|---|---|---|---|---|
Phase 1 Study of ER-100 in Optic Neuropathies (Glaucoma and NAION) ER-100: modified AAV-delivered partial epigenetic reprogramming (OCT4, SOX2, KLF4) to retinal ganglion cells, with 8-week oral doxycycline regimen to control transgene expression | Life Biosciences | Open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION) | Phase 1 (First-in-Human) | NCT07290244 | Enrolling — trial started March 2, 2026 |
Turn Bio Skin Rejuvenation (Planned) ERA (Epigenetic Reprogramming of Age) mRNA delivered topically or locally to skin cells | Turn Biotechnologies | Skin aging / dermatologic conditions | Pre-IND | IND planned | Planning clinical trial initiation for 2026 |
Retro Biosciences RTR242 Autophagy Trial RTR242: small-molecule autophagy activator designed to restore cellular waste clearance | Retro Biosciences | Age-related autophagy decline | Phase 1 (Australia) | Retro-AU-2025 | Initiated 2025 |
STAY Study - LOY-002 for Canine Lifespan Extension LOY-002: Daily oral tablet targeting metabolic dysfunction associated with aging (GLP-1/IGF-1 pathways) | Loyal | Lifespan extension in senior dogs (10+ years, 14+ lbs) | Pivotal (conditional approval pathway) | STAY (Loyal) | Active. FDA accepted RXE (efficacy) and TAS (safety) packages. Recruiting. |
Regulatory Milestones
Pre-IND programs with significant regulatory progress but not yet in clinical trials.
YouthBio Therapeutics
Alzheimer's disease
YB002: AAV gene therapy delivering partial reprogramming factors to dentate gyrus hippocampal neurons
FDA confirmed preclinical bioactivity and supports path to first-in-human trial. CMC and pilot tox studies underway. Would be first partial reprogramming therapy for the brain. Estimated clinical entry ~2028.
Key Figures
The scientists, founders, and investors shaping the field — 25 individuals across 4 categories.
Pioneers
Sir John B. Gurdon
Father of Nuclear Reprogramming
Proved in 1962 that mature, specialised cells retain all genetic information needed to form any cell type, laying the conceptual foundation for all reprogramming work.
Gurdon Institute, University of Cambridge (1933-2025)
Shinya Yamanaka
Discoverer of Induced Pluripotent Stem Cells (iPSCs)
Identified the four transcription factors (Oct4, Sox2, Klf4, c-Myc -- the Yamanaka factors) that can reprogram adult cells back to a pluripotent state. This discovery is the bedrock of all partial reprogramming research.
Gladstone Institutes & UCSF; Director Emeritus, CiRA, Kyoto University; Senior Scientist, Altos Labs
Kazutoshi Takahashi
Co-discoverer of iPSCs
Lead author on the landmark 2006 Cell paper with Yamanaka that first demonstrated induced pluripotent stem cells from mouse fibroblasts, and the 2007 paper extending the work to human cells.
CiRA, Kyoto University; Gladstone Institutes
Researchers
Juan Carlos Izpisua Belmonte
Pioneer of Partial Reprogramming In Vivo
First demonstrated in 2016 that cells can be partially reprogrammed -- rejuvenated without losing their identity -- opening the door to therapeutic applications. Discovered that aging involves a pervasive 'mesenchymal drift' that partial reprogramming can reverse.
Altos Labs (Founding Scientist & SVP); formerly Salk Institute
David Sinclair
Proponent of Information Theory of Aging & Epigenetic Reprogramming
Proposed that aging is primarily caused by loss of epigenetic information, not DNA mutations. Demonstrated OSK (Oct4, Sox2, Klf4) gene therapy can restore vision in aged mice by resetting the epigenome. Co-founded Life Biosciences to bring epigenetic reprogramming to the clinic.
Harvard Medical School, Paul F. Glenn Center for Biology of Aging Research; Co-founder, Life Biosciences
Steve Horvath
Creator of the Epigenetic Clock
Developed the first pan-tissue epigenetic clock (2013) based on DNA methylation at 353 CpG sites, enabling precise measurement of biological age. Without this biomarker, measuring whether reprogramming actually 'rejuvenates' cells would be impossible.
Principal Investigator, Altos Labs Cambridge Institute of Science; formerly UCLA
Morgan Levine
Computational Biologist & Aging Clock Developer
Developed next-generation epigenetic clocks (PhenoAge) and computational methods to quantify system dysregulation during aging. Leads AI/ML efforts at Altos Labs to model cellular perturbation responses.
VP of Computation, Altos Labs; formerly Yale University School of Medicine
Wolf Reik
Epigenetic Reprogramming in Development & Aging
Developed protocols for substantial rejuvenation of human cells without loss of cell identity. Pioneered single-cell multi-omics technologies to understand cell fate decisions during development and how they degrade during aging.
Director, Altos Labs Cambridge Institute of Science; Honorary Group Leader, Babraham Institute
Manuel Serrano
Discoverer of p16 & Expert on Cellular Senescence and In Vivo Reprogramming
Discovered the p16 tumour-suppressor gene (1993), a master regulator of cellular senescence. Now focuses on the intersection of senescence and partial reprogramming, seeking pharmacological and dietary interventions that mimic partial reprogramming for rejuvenation.
Principal Investigator, Altos Labs Cambridge Institute of Science; formerly IRB Barcelona
Alejandro Ocampo
Chemical Reprogramming for Aging Reversal
Trained under Izpisua Belmonte at the Salk Institute, then established his own lab focused on chemical (non-genetic) approaches to partial reprogramming. Demonstrated that small molecules can replicate the rejuvenating effects of Yamanaka factors with better safety profiles.
University of Lausanne, Faculty of Biology and Medicine; Founder, EPITERNA
Yuancheng Lu
Developer of OSK Gene Therapy for Vision Restoration
Engineered the AAV-delivered OSK (Oct4, Sox2, Klf4) gene therapy that restored vision in aged mice and glaucoma models, providing the first proof that complex tissues can be safely rejuvenated via partial reprogramming in vivo.
Sinclair Lab, Harvard Medical School
Hongkui Deng
Pioneer of Fully Chemical Reprogramming
Developed the world's first method to generate human pluripotent stem cells using only small molecules, eliminating the need for any genetic modification. This chemical-only approach has major safety advantages for therapeutic applications.
Peking University, School of Life Sciences
Nir Barzilai
Leader of the TAME Trial & Geroscience Advocate
Designed the TAME (Targeting Aging with Metformin) clinical trial, the first FDA-approved trial template that treats aging itself as the indication rather than individual diseases. This regulatory framework paves the way for future reprogramming therapies to target aging directly.
Albert Einstein College of Medicine; Director, Institute for Aging Research
Alex Zhavoronkov
AI-Driven Aging Biomarkers & Drug Discovery
Pioneered deep learning-based biological age clocks and applied generative AI to discover geroprotective drug candidates. Co-founded the annual ARDD (Aging Research and Drug Discovery) conference, the field's premier annual gathering.
Founder & CEO, Insilico Medicine; Founder, Deep Longevity; Co-founder, ARDD Conference
Joao Pedro de Magalhaes
Computational Genomics of Aging & Rejuvenation
Combines computational biology with experimental approaches to study aging. Maintains the most comprehensive public databases on aging biology (GenAge, AnAge, DrugAge, CellAge). As CSO of YouthBio, guides the development of partial reprogramming gene therapies.
University of Birmingham, Chair of Molecular Biogerontology; CSO, YouthBio Therapeutics
Aubrey de Grey
Architect of the SENS Damage-Repair Framework
Proposed the Strategies for Engineered Negligible Senescence (SENS) framework treating aging as an engineering problem with seven categories of damage. While not directly focused on reprogramming, his damage-repair paradigm provides context for where reprogramming fits in the broader anti-aging toolkit.
Founder & CSO, LEV Foundation (Longevity Escape Velocity)
Vittorio Sebastiano
Developer of ERA (Epigenetic Reprogramming of Aging) Technology
Developed the ERA platform that uses mRNA-delivered transcription factor cocktails to achieve epigenetic rejuvenation of adult cells while preserving cell identity. This mRNA-based approach avoids the risks of permanent genetic modification.
Stanford School of Medicine, Associate Professor of OB/GYN; Head of Research, Turn Biotechnologies
Andrew Steele
Science Communicator & Longevity Advocate
Transitioned from computational biology at the Crick Institute to full-time science communication, making aging research accessible to the public. Co-founded The Longevity Initiative to bridge research and policy.
Director & Co-Founder, The Longevity Initiative; formerly Francis Crick Institute
Industry Leaders
Hal Barron
Leader of the Largest Cellular Rejuvenation Company
Built and leads Altos Labs, the best-funded company in the reprogramming space ($3B). Previously led R&D at GSK and was president of R&D at Calico (Google's aging company). Designed Altos to integrate academic freedom with industry focus on translating reprogramming science into medicines.
CEO, Founder & Board Co-Chair, Altos Labs
Rick Klausner
Scientific Architect of Altos Labs
Co-founded Altos Labs and serves as its chief scientist, shaping the scientific strategy. Former director of the National Cancer Institute. Organised the initial meetings that brought together the scientists who would form Altos Labs.
Chief Scientific Advisor, Founder & Board Co-Chair, Altos Labs
Daphne Koller
AI/ML-Driven Drug Discovery for Aging
Built insitro to integrate machine learning with wet-lab biology for drug discovery, including aging-related targets. Previously served as Chief Computing Officer at Calico (Google's aging company). Her approach of using ML to model disease mechanisms rather than just optimise molecules is shaping how reprogramming targets are identified.
Founder & CEO, insitro
Joe Betts-LaCroix
Leading Retro Bio's Multi-Pronged Longevity Programs
Co-founded Retro Biosciences in 2020 to extend healthy human lifespan by 10 years through cellular reprogramming, autophagy enhancement, and plasma-inspired therapies. Partnered with OpenAI to apply AI to improve reprogramming efficiency by 50x.
Co-founder & CEO, Retro Biosciences
Yuri Deigin
Bringing Partial Reprogramming Gene Therapy to the Clinic
Founded YouthBio Therapeutics to develop rejuvenation gene therapies based on partial reprogramming by Yamanaka factors. Targeting brain aging with AAV-delivered partial reprogramming, with the FDA supporting their path toward first-in-human trials.
Co-founder & CEO, YouthBio Therapeutics
Investors & Founders
Brian Armstrong
Tech Billionaire Backing Epigenetic Reprogramming
Co-founded NewLimit in 2022 to develop medicines that target aging through epigenetic reprogramming. The company has identified 20+ transcription factor sets that restore youthful phenotypes in aged hepatocytes from testing 3,000+ combinations.
CEO, Coinbase; Co-founder, NewLimit
Sam Altman
Largest Individual Investor in Cellular Reprogramming
Provided the entire $180M seed round for Retro Biosciences and is joining the $1B Series A. Facilitated the OpenAI-Retro partnership that used GPT-4b to optimise Yamanaka factors, achieving a 50x improvement in reprogramming efficiency -- demonstrating the power of AI in accelerating reprogramming research.
CEO, OpenAI; Lead investor, Retro Biosciences
Academic Labs
The research groups producing the foundational science behind cellular reprogramming.
Salk Institute for Biological Studies
Juan Carlos Izpisua Belmonte (now at Altos Labs)
La Jolla, CA
Pioneered in vivo partial reprogramming using cyclic OSKM expression in progeroid and naturally aged mice.
First demonstration that cyclic partial reprogramming extends lifespan by 30% in progeria mice (2016). Showed rejuvenation of mitochondria and epigenetic clocks without tumor formation.
Belmonte closed his Salk lab to join Altos Labs. Work forms the scientific foundation for most reprogramming companies.
Harvard Medical School / Blavatnik Institute
David Sinclair
Boston, MA
Information Theory of Aging. OSK (3-factor) gene therapy to reverse epigenetic age in specific tissues. DNA methylation clocks.
REVIVER mice: restored vision in aged glaucoma mice using OSK factors (2020). Co-founded Life Biosciences, whose ER-100 became the first partial reprogramming therapy to enter human clinical trials (2026).
Co-founder of Life Biosciences. Scientific advisor to multiple longevity companies. Published the 'Information Theory of Aging' framework.
Harvard Medical School / Wyss Institute
George Church
Boston, MA
Multiplex gene therapy for aging using AAV vectors delivering longevity-associated genes (FGF21, sTGFbetaR2, klotho).
Demonstrated that a single AAV gene therapy cocktail can reverse multiple age-related conditions simultaneously in mice. Spawned Rejuvenate Bio, Marble Therapeutics, GC Therapeutics, and other startups.
Lab has spun out 10+ companies in the longevity space. Rejuvenate Bio, Marble Therapeutics, and GC Therapeutics (raised $75M in 2024) are direct spinouts.
Stanford University
Vittorio Sebastiano
Stanford, CA
Transient reprogramming of human cells using non-integrating mRNA expression of Yamanaka factors. Rejuvenation of multiple cell types.
Published landmark study showing 'dramatic rejuvenation across all hallmarks but one in all cell types tested.' Demonstrated restoration of mitochondrial efficiency and protein homeostasis in aged cells. 2025 Cell publication on reversing mesenchymal drift.
Co-founder of Turn Biotechnologies. Research provides scientific basis for mRNA-based reprogramming approaches.
Babraham Institute
Wolf Reik
Cambridge, UK
Epigenetic clocks, maturation-phase reprogramming, and single-cell DNA methylation aging. Developed 'time jump' partial reprogramming protocol.
Demonstrated that reprogramming 60-year-old fibroblasts to the maturation phase (then stopping) rejuvenated them to a 25-30 year-old state by transcriptome, methylome, and collagen function (2022). Developed scEpiAge single-cell epigenetic age predictor (2024).
Former head of Epigenetics programme at Babraham. Research established the concept of 'maturation-phase' reprogramming distinct from full iPSC conversion.
Altos Labs (Institute of Science)
Shinya Yamanaka (Scientific Advisor)
Redwood City, CA / Cambridge, UK / San Diego, CA
Cellular rejuvenation programming. Original discoverer of OSKM factors (Nobel Prize 2012). Advises on safe therapeutic application of reprogramming.
2006: Discovery of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that reprogram somatic cells to pluripotent state -- the foundation of all partial reprogramming research.
Nobel laureate. Senior Scientific Advisor at Altos Labs. His original iPSC discovery spawned the entire field.
Funding Ecosystem
12 venture funds, foundations, and company builders financing the longevity revolution.
Hevolution Foundation
Non-profit Foundation (Saudi Royal Decree)
$400M+ deployed; $1B/year mandate
Largest dedicated healthspan funder globally. Grants (HF-GRO program: $230M for preclinical aging biology) and impact investments in aging therapeutics.
Khosla Ventures
Venture Capital
$15B+ total AUM
Most prolific longevity-focused VC by deal count. Invests across reprogramming, senolytics, and AI-driven drug discovery for aging.
The Longevity Fund
Venture Capital (Seed/Series A)
$37M under management
Dedicated longevity VC. Invests in breakthrough companies targeting the biology of aging at seed and Series A stages.
ARCH Venture Partners
Venture Capital
$4B+
Major life sciences VC. Led the largest single investment in longevity history with Altos Labs.
Founders Fund (Peter Thiel)
Venture Capital
$11B+
Deep tech and moonshot VC with significant longevity thesis. Funds companies addressing fundamental aging biology.
Cambrian Bio / Apollo Ventures
Company Builder / VC
Undisclosed
Longevity-focused company builder. Creates and funds portfolio companies targeting different hallmarks of aging.
Apollo Health Ventures
Venture Capital
$180M fund
Transatlantic early-stage VC focused exclusively on co-founding and investing in age-related healthcare companies.
Kizoo Technology Capital
Venture Capital
Undisclosed (17 funds)
German VC focused on rejuvenation biotechnology. Active investor in senolytic and reprogramming companies.
Age1
Venture Capital
Undisclosed
Dedicated longevity VC funding breakthrough companies addressing core challenges of the aging field.
Kleiner Perkins
Venture Capital
$18B+
Legendary VC with growing longevity thesis. Led NewLimit's $130M Series B in 2025.
Methuselah Foundation / Methuselah Fund
Non-profit / Impact Fund
Undisclosed
Pioneer longevity non-profit (est. 2003). Mission to make 90 the new 50 by 2030. Awards grants and prizes for aging research.
LongevityTech Fund
Venture Capital
Undisclosed (31 funds)
European longevity-focused VC investing across the aging intervention spectrum from biotech to digital health.
“We are at the very beginning of a transformation in medicine — from treating disease to restoring youth.”
THE LANDSCAPE IS STILL FORMING. THIS PAGE WILL GROW.